激活α4β2尼古丁乙酰胆碱受体可缓解大鼠芬太尼诱导的呼吸抑制
该研究在大鼠离体脑干脊髓和活体模型中测试激活尼古丁受体能否逆转阿片类呼吸抑制而不影响镇痛。结果显示选择性α4β2激动剂A85380快速逆转芬太尼所致呼吸频率下降,并增强芬太尼镇痛,而α7激动剂无效。
要点
- α4β2尼古丁受体激动剂A85380可快速逆转芬太尼诱导的呼吸抑制。
- A85380与芬太尼或瑞芬太尼合用减少呼吸抑制和呼吸暂停。
- A85380还增强芬太尼镇痛效果,α7激动剂PNU282987无效。
核心结论
- 靶向α4β2尼古丁乙酰胆碱受体有潜力改善疼痛控制并减少阿片诱导的呼吸抑制和过量。
研究设计与样本
- 使用大鼠离体脑干脊髓和延髓切片标本测量呼吸神经放电,活体用体积描记、痛觉测试和翻正反射评估呼吸、镇痛和镇静。
主要发现
- 在成年大鼠活体中,A85380(0.03 mg/kg)快速稳健逆转芬太尼所致呼吸频率下降(3分钟后为对照的93.4±33.7% vs 溶剂对照31±20.5%,n=8每组,P<0.001)。
- A85380(0.06 mg/kg)与芬太尼或瑞芬太尼合用显著减少呼吸抑制和呼吸暂停,并增强芬太尼镇痛(Hargreaves抬脚潜伏期14.4±2.8 s vs 溶剂11.3±2.4 s,n=8每组,P=0.013)。
- A85380(0.06 mg/kg)与芬太尼合用减少福尔马林诱导的伤害性行为持续时间(2.5±2.4 min vs 溶剂5.4±2.7 min,n=8每组,P=0.029)。
临床怎么用
- α4β2尼古丁受体激动可能作为辅助策略,在阿片镇痛同时减少呼吸抑制风险。
局限性
- 研究为大鼠实验,结果尚未在人体验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioid analgesics are widely used for treatment of acute, postoperative, and chronic pain. However, activation of opioid receptors can result in severe respiratory depression. There is an unmet clinical need to develop a pharmacologic therapy to counter opioid-induced respiratory depression without interfering with analgesia. Further, additional advances to confront accidental lethal overdose with the use of fentanyl and other opioids are needed. Here, the authors test the hypothesis that activation of nicotinic receptors expressed within respiratory rhythm-generating networks would counter opioid-induced respiratory depression without compromising analgesia. METHODS: Respiratory neural discharge was measured using in vitro brainstem-spinal cord and medullary slice rat preparations. In vivo, plethysmographic recording, nociception testing, and righting reflexes were used to examine respiratory ventilation, analgesia, and sedation, respectively. RESULTS: The administration of nicotine, selective α4β2 nicotinic receptor agonist A85380, but not α7 nicotinic receptor agonist PNU282987, reversed opioid-induced respiratory depression in neonatal pups in vitro and in vivo. In adult rats in vivo, administration of A85380 (0.03 mg/kg), but not PNU282987, provides a rapid and robust reversal of fentanyl-induced decrease in respiratory rate (93.4 ± 33.7% of control 3 min after A85380 vs. 31 ± 20.5% of control after vehicle, n = 8 each, P < 0.001), without marked side effects. The coadministration of A85380 (0.06 mg/kg) with fentanyl or remifentanil markedly reduced respiratory depression and apneas, and enhanced the fentanyl-induced analgesia, as evidenced by increased paw withdrawal latency in Hargreaves plantar test (14.4 ± 2.8 s vs. vehicle: 11.3 ± 2.4 s, n = 8 each, P = 0.013) and decreased formalin-induced nocifensive duration (2.5 ± 2.4 min vs. vehicle: 5.4 ± 2.7 min, n = 8 each, P = 0.029). CONCLUSIONS: The novel strategy of targeting α4β2 nicotinic acetylcholine receptors has the potential for advancing pain control and reducing opioid-induced respiratory depression and overdose.
引用
- Ren J, Ding X, Greer JJ, et al. Activating α4β2 Nicotinic Acetylcholine Receptors Alleviates Fentanyl-induced Respiratory Depression in Rats. Anesthesiology. 2019. PMID: 31008764. doi:10.1097/ALN.0000000000002676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。